Quantcast

Latest Cancer vaccine Stories

2014-09-05 20:21:03

Horses with melanoma are the subject of this major clinical study TAMPA, Fla., Sept. 5, 2014 /PRNewswire/ -- Morphogenesis Inc., the biotechnology firm developing ImmuneFx(TM), a cancer vaccine that has improved the longevity and quality of life for dogs, cats and horses, announces that a formal equine clinical trial for the direct injection form of the vaccine will begin later this month at a large equine facility in Missouri. Pat Lawman, PhD., co-founder and CEO of Morphogenesis...

2014-09-04 16:27:07

Unique Multivalent WT1 Vaccine to be developed across hematological malignancies and solid tumors NEW YORK, Sept. 4, 2014 /PRNewswire/ -- SELLAS Life Sciences Group (SELLAS), a Swiss-based development-stage biopharmaceutical company today announced that it has signed an exclusive global collaboration and license agreement with Memorial Sloan Kettering Cancer Center (MSK) for the development, marketing, and commercialization of MSK's proprietary WT1 cancer vaccine. "This...

2014-08-28 12:29:01

Key Program Part of Recent Merger with MabVax Therapeutics, Inc. SAN DIEGO, Aug. 28, 2014 /PRNewswire/ -- Telik, Inc. (OTCQB: TELK), a clinical stage oncology drug development company that merged with MabVax Therapeutics, Inc. on July 8, 2014, announced today it has made significant progress related to the development of its lead antibody program designated 5B1. The fully-human antibody was recovered using the Company's internally developed antibody discovery platform. These...

2014-08-28 08:27:53

WHITE PLAINS, N.Y., Aug. 28, 2014 /PRNewswire-USNewswire/ -- The Leukemia & Lymphoma Society (LLS) and OncoPep have entered a partnership to advance an experimental cancer vaccine to treat patients with smoldering multiple myeloma (SMM), an asymptomatic stage of myeloma. The partnership is through LLS's Therapy Acceleration Program® (TAP), through which LLS forges collaborations with biotechnology companies to help bring therapies to patients faster. OncoPep is developing a...

2014-08-25 12:26:05

Contract Results from Recent Merger with MabVax Therapeutics, Inc. SAN DIEGO, Aug. 25, 2014 /PRNewswire/ -- Telik, Inc. (OTCQB: TELK), a clinical stage oncology drug development company that merged with MabVax Therapeutics, Inc. on July 8, 2014, announced today it has received a $1.5 million contract for the Phase 2 portion of a Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI). The contract is intended to support a major portion of the...

2014-08-25 08:27:12

Initial Closing is for $10 Million FREDERICK, Md., Aug. 25, 2014 /PRNewswire/ -- Vaccinogen, Inc., (OTC.QB: VGEN) a cancer immunotherapy development company, announced today that it completed the initial closing of a private placement of $80 million of units and common stock. Vaccinogen received gross proceeds of $10 million in this first closing. http://photos.prnewswire.com/prnvar/20140825/139089 Vaccinogen is preparing to start ACTIVE, a confirmatory Phase IIIb pivotal...

2014-08-12 23:04:31

MicroVAX, LLC, National Cancer Center (NCC), Singapore, and Singapore Clinical Research Institute (SCRI) joint media release, August 12, 2014 Manassas, Virginia (PRWEB) August 12, 2014 MicroVAX, LLC, a biotech company located in Manassas, Virginia announced today the commencement of a phase I clinical trial for its unique and proprietary vaccine platform that allows under the provisions of an FDA IND entry of patients with cancers of the breast, prostate, colon, ovary and lung, that have...

2014-08-11 08:28:16

TAMPA, Fla., Aug. 11, 2014 /PRNewswire/ -- Morphogenesis Inc., the Tampa-based biotech company that developed the ImmuneFx(TM) cancer vaccine for dogs, cats and horses, announces that it has chosen Florida Veterinary Referral Center & 24-Hour Emergency Hospital in Estero, FL, as the newest exclusive provider of the ImmuneFx(TM) therapy process for companion animals. ImmuneFx(TM) primes and educates the pet's own immune system to recognize and kill cancer cells without harming...

2014-08-06 12:28:13

Study Correlates Immune Response with Improved Survival in Prostate Cancer Patients after Receiving the Antigen Express Novel Immunotherapeutic AE37 WORCESTER, Mass. and TORONTO, Aug. 6, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced publication of a follow-up study from a Phase I clinical trial of the immunotherapeutic agent AE37 in patients with prostate cancer. The study demonstrates an association between a specific immune...

2014-07-28 10:33:11

Dartmouth-Hitchcock Norris Cotton Cancer Center Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center are exploring ways to wake up the immune system so it recognizes and attacks invading cancer cells. Tumors protect themselves by tricking the immune system into accepting everything as normal, even while cancer cells are dividing and spreading. One pioneering approach, discussed in a review article published this week in WIREs Nanomedicine and Nanobiotechnology, uses...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related